More Mesoblast Limited news
Mesoblast LimitedASX: MSB

FDA Clears Heart Disease Trial At Boston Childrens Hospital

Apr 3, 2017 at 11:31 PM EDT · Issued by Mesoblast Limited

Filed with ASX · Apr 3, 2017 at 11:31 PM EDT

On 6ix: 6ix.com/news/fda-clears-heart-disease-trial-at-boston-childrens-hospital

Watch Mesoblast's latest call↗Mesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call↗

Mesoblast Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Mesoblast Limited on 6ix

Earlier from Mesoblast

  • Process Initiated For CHF P3 Interim AnalysisMar 30, 2017
  • Mesoblast Raises US$40 MillionMar 26, 2017
  • Durable Three Year Outcomes in Disc DiseaseMar 15, 2017
  • FDA Grants Mesoblast Fast Track Designation For GVHDMar 6, 2017
  • Positive Nine Month RA Results For Mesoblast Cell TherapyFeb 15, 2017

Later from Mesoblast

  • Mesoblast Receives A$3.7m From Aus Govt For R&DApr 5, 2017
  • Successful Interim Analysis in Phase 3 Heart Failure TrialApr 9, 2017
  • Third Quarter Financial Results On Form 6-KMay 24, 2017
  • MSB Provides Q3 Operational Highlights and Financial ResultsMay 24, 2017
  • Mesoblast RA Results Presented At EULAR CongressJun 22, 2017
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer